Based on its advanced Graft-Versus-Host Disease (GVHD) research capabilities, Creative Biolabs provides global customers with a full range of GVHD diagnostic, prevention, and drug development services, including target discovery, biomarker detection, structural studies, drug screening, antibody discovery, and expression preparation, and drug activity testing. Our goal is to become a leader in the field of precision control of GVHD through continuous technological innovation and service optimization and make unremitting efforts to improve the quality of life of patients.
Introduction
GVHD is the major cause of postoperative complications and non-recurrent death in hematopoietic cell transplantation (HCT). The clinical manifestations of GVHD have been divided into three syndromes: acute GVHD (aGVHD), chronic GVHD (cGVHD), and GVHD overlapping syndrome.
The pathogenesis of GVHD is intricate, the manifestations are multifarious, the individual variations are diverse, the disease course is protracted, and it can even be life-threatening. As a result, Creative Biolabs attaches significant importance to the prevention and therapy of GVHD and has established a comprehensive set of GVHD-related diagnoses, biomarker detection, and therapy research analysis systems to facilitate the in-depth exploration of GVHD mechanism and the development of new GVHD drugs.
Services
As a premier GVHD diagnostic CRO company, Creative Biolabs has consistently concentrated on applying advanced detection technology to the precise diagnosis of GVHD. Currently, we have established the world's leading GVHD pathophysiological diagnostic technology platform, capable of providing early inflammation analysis of GVHD tissue injury, thymus injury, and T/B cell immune dysregulation analysis caused by GVHD chronic inflammation, as well as GVHD induced tissue fibrosis analysis. From HLA detection to early screening, from auxiliary diagnosis to concomitant diagnosis and relapse monitoring, we are dedicated to offering full support for GVHD.
To effectively prevent the development of GVHD, we provide a diverse array of GVHD biomarker prediction analysis services. At the genetic, protein, and cellular levels, various biomarkers for GVHD and their metabolites, such as miR-423 and miR-199a-3p, have been detected by our labs to reveal the potential GVHD process within the human body. Moreover, our scientists have enhanced the GVHD predictive performance by integrating multiple markers at different levels. Our GVHD biomarker assay is simple and relatively inexpensive, with standardized results and high sensitivity and specificity.
GVHD is mainly treated with traditional glucocorticoid-based therapy, but it can cause many adverse reactions and complications. Therefore, Creative Biolabs has been working to develop new therapeutic options to provide effective and safe therapy solutions for GVHD. Nowadays, we have configured a full range of targeted GVHD drug development, analysis, and validation systems based on different GVHD-mediated immunosuppression and molecular signaling pathways strategies. Among them, we have extensive experience in targeted therapies, especially monoclonal antibody development, and immunotherapies such as mTOR inhibitors, steroid drugs, enzyme inhibitors, and immunosuppressive drugs. Our services cover the full range of early-stage GVHD drug development needs, including but not limited to, target protein expression and structure studies, drug screening, antibody discovery and expression preparation, and drug activity testing.
Fig.1 MOA of GVHD Therapies.1
As an innovative CRO company focused on GVHD treatment, Creative Biolabs provides long-term services in the field of GVHD innovative drugs or novel therapies development. We are committed to the integration of cutting-edge technologies such as genetic testing, big data analysis, and artificial intelligence, and promote the change of diagnosis and treatment of GVHD with leading diagnostic technology. If you are interested in our services, please feel free to contact us.
Reference
-
Kovalenko, Iuliia, et al. "Novel Pharmacological Treatment Options of Steroid-Refractory Graft-versus-Host Disease." Advances in Hematology 2023.1 (2023): 9949961.
For Research Use Only | Not For Clinical Use
Download our brochure